Imaging scan using 18F-G1 to study immunotherapy in several cancers
Studies a 18F-G1 PET scan in adults with solid tumors or blood cancers receiving immunotherapy.
Plain-language title generated from the registry record
Registry title: The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a solid tumor or a blood cancer who are about to start immunotherapy for the first time. It tests 18F-G1 PET/CT scans.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Cancer confirmed by tissue examination. At least one tumor that can be measured on scans (RECIST 1.1). Expected survival of 6 months or more. ECOG performance status of 2 or lower.
- Earlier treatment
- No earlier immunotherapy. Immunotherapy (alone or combined) must be planned by the multidisciplinary team.
Main reasons for not taking part
- Pregnancy, lactation or planning a pregnancy
- Another cancer at the same time
- Autoimmune disease, or long-term steroid or immunosuppressive treatment
- Severe heart or blood vessel disease, or severe liver or kidney failure
- Radiotherapy or interventional therapy during the immunotherapy
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07039474, who can take part
Where in China
- Peking University First HospitalBeijing, ChinaContact: Meng LiuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University First Hospital
- Trial code
- NCT07039474
- Record updated
- 28 September 2026
- Original description
The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapyRead full original descriptionShow less
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy
Inclusion: Subjects diagnosed with a malignant tumor by histopathology who are going to receive immunotherapy (monotherapy or combined immunotherapy) recommended by the multidisciplinary team; Subjects didn't receive previous immunotherapy; There exists at least one measurable target lesion according to the RECIST 1.1; ECOG performance status≤2; The expected survival time is ≥6 months; Effective contraceptive measures will be adopted during the study period and within 6 months after the study; Willing and able to fully understand and sign the informed consent form.
Exclusion: Receiving radiotherapy or interventional therapy during the immunotherapy; 18F-G1 PET/CT or 18F-FDG PET/CT is not performed in our department, or the interval between baseline imaging and immunotherapy is more than 30 days; Combined with other malignant tumor; Diagnosed with autoimmune disease, or have long history of systemic steroid hormone therapy or immunosuppressive therapy; Having a history of severe cardiovascular disease, severe hepatic and renal insufficiency; Women in the preconception period, pregnancy, or lactation period.